NPTX Stock Overview
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Neuropathix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0003 |
| 52 Week High | US$0.015 |
| 52 Week Low | US$0.0002 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -98.05% |
| 33 Year Change | -99.92% |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| NPTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | -2.9% |
| 1Y | -98.1% | 18.9% | 16.6% |
Return vs Industry: NPTX underperformed the US Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: NPTX underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| NPTX volatility | |
|---|---|
| NPTX Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 14.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NPTX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NPTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 6 | Dean Petkanas | neuropathix.com |
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020.
Neuropathix, Inc. Fundamentals Summary
| NPTX fundamental statistics | |
|---|---|
| Market cap | US$29.31k |
| Earnings (TTM) | -US$3.82m |
| Revenue (TTM) | US$359.46k |
0.0x
P/S Ratio0.0x
P/E RatioIs NPTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NPTX income statement (TTM) | |
|---|---|
| Revenue | US$359.46k |
| Cost of Revenue | US$542.89k |
| Gross Profit | -US$183.43k |
| Other Expenses | US$3.64m |
| Earnings | -US$3.82m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NPTX perform over the long term?
See historical performance and comparison